Clinical research study to assess ability of eltrombopag to induce sustained remission in subjects with Immune Thrombocytopenia who are refractory or relapsed after first line steroids TAPER

Clinical research study to assess ability of eltrombopag to induce sustained remission in subjects with Immune Thrombocytopenia who are refractory or relapsed after first line steroids TAPER
Recruiting
18 years - 99 years
All
Phase 2
2 participants needed
1 Location

Brief description of study

This research study is to find out if the study drug eltrombopag also known as Revolade/Promacta can help those who have Immune Thrombocytopenia (ITP.)  The study will determine if subjects are able to stop eltrombopag treatment while maintaining acceptable platelet levels after their disease has become resistant to treatment or has a reoccurrence of symptoms after initial treatment with steroids. This study will enroll subjects who are at least 18 years old, have refractory ITP and have failed first line treatments.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Immune Thrombocytopenia
  • Age: 18 years - 99 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 833549

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.